STRO Stock Forecast & Price Target

Sutro Biopharma is viewed favorably because STRO-004 is already showing multi-histology activity in a heavily pretreated, TF-unselected population, with confirmed and ongoing unconfirmed partial responses in PDAC, HNSCC, and NSCLC, while its safety profile appears differentiated by low discontinuation, limited high-grade ocular or neuropathic toxicity, and supportive PK. The broader pipeline strengthens the thesis, as STRO-006 delivered stronger preclinical tumor control than comparators and is set to enter Ph 1 in 3Q26, while STRO-227 showed regression in acquired-resistance models and is on track for an IND submission in 2026. Financially, the company ended the quarter with $164.3MM in cash, cash equivalents, and marketable securities, which it expects to fund operations into at least 2Q28, giving it runway to advance multiple wholly owned assets and potentially capture additional value from the Astellas collaboration.

Sutro Biopharma is vulnerable to disappointing clinical data from its lead ADC candidates, a risk that could force lower assumptions for market penetration, higher discount rates, and even no approval if efficacy or safety fall short in current or future trials. Its broader pipeline of partnered and wholly owned discovery and preclinical assets adds further uncertainty, while FDA and foreign regulatory hurdles, plus dependence on partners for development and commercialization, compound execution risk. Competitive pressure is also significant, and despite being well-funded with cash, cash equivalents, and short-term investments, it may still need additional equity financing to complete development.